OrthoPediatrics Q1 revenue up 41% to $44.7M; raises FY 2024 guidance to $200-203M

ORTHOPEDIATRICS CORP

2024-Q1 EPS reported -$0.34 revenue$44,685,000

Total revenue $44.7M (+41% YoY); U.S. +44%, international +33%.
Net loss $7.8M ($0.34 loss per share) vs $6.8M ($0.30) a year ago.
Adjusted EBITDA loss improved to $1.1M from $2.1M in Q1 2023.
Raised full-year 2024 revenue guidance to $200-203M from prior $197-200M.
Boston O&P acquisition contributed; cash & restricted cash $49.7M at March 31.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2024 results: revenue $44.7 million, net income $7.8 million, EPS $0.34 per basic and diluted share. Guidance raised.

Period: the first quarter ended March 31, 2024
Revenue: $44.7 million
Net income: $7.8 million
EPS: $0.34 per basic and diluted share
Guidance: raised
Result: reported results

Exact text from the filing

Quarter 2024 and Business Highlights • Helped nearly 28,000 children in the first quarter of 2024, an increase of 47% from the first quarter 2023 • Generated total revenue of $44.7 million for the first quarter of 2024, up 41% from $31.6 million in first quarter 2023; domestic revenue increased 44% and international revenue increased 33% in the quarter • Grew

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-24-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.